Until share value is unlocked, Cantor’s Louise Chen finds it difficult to recommend TEVA shares.
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Ampio Pharmaceuticals …
New Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) CEO Kare Schultz held his first call today to dive into the fresh restructuring strategy to …
Maxim’s Jason Kolbert is keeping his focus peeled to the Omeros pipeline, even though he welcomes the FDA victory for Omidria.
Why patient deaths don’t necessarily scuttle Global Blood’s chances for voxelotor’s clinical success.
ASH data offers insight into Gilead Sciences’ lymphoma drug Yescarta; Maxim’s Jason McCarth weighs in.
Proteostasis Therapeutics Inc (NASDAQ:PTI) are taking off like a rocket through the market, up 162% on the heels of a key victory in …
Maxim’s Jason Kolbert is betting on SPHS to “unlock” share value with prostate cancer asset topsalysin.
Should you pull the trigger on Teva? Guggenheim’s Rohit Vanjani is fine staying sidelined.
The annual meeting for the American Society of Hematology (ASH) has just kicked off. Running from Dec.
